Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Advanced Enzyme Technologies Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹239.59Overvalued by 19.87%vs CMP ₹299.00

P/E (23.2) × ROE (9.5%) × BV (₹133.00) × DY (1.74%)

₹182.58Overvalued by 38.94%vs CMP ₹299.00
MoS: -63.8% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹251.4022%Over (-15.9%)
Graham NumberEarnings₹201.8116%Over (-32.5%)
Earnings PowerEarnings₹93.2813%Over (-68.8%)
DCFCash Flow₹183.9713%Over (-38.5%)
Net Asset ValueAssets₹132.577%Over (-55.7%)
EV/EBITDAEnterprise₹205.029%Over (-31.4%)
Earnings YieldEarnings₹136.107%Over (-54.5%)
ROCE CapitalReturns₹220.859%Over (-26.1%)
Revenue MultipleRevenue₹85.365%Over (-71.5%)
Consensus (9 models)₹182.58100%Overvalued

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 4.9%

*Investments are subject to market risks

Analyst Summary

Advanced Enzyme Technologies Ltd operates in the Pharmaceuticals segment, NSE: ADVENZYMES | BSE: 540025, current market price is ₹299.00, market cap is 3,347 Cr.. At a glance, stock P/E is 23.2, ROE is 9.54 %, ROCE is 13.1 %, book value is 133, dividend yield is 1.74 %. The latest intrinsic value estimate is ₹182.58, around 38.9% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹637 Cr versus the prior period change of 2.1%, while latest net profit is about ₹134 Cr with a prior-period change of -2.2%. The 52-week range shown on this page is 367/252, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisAdvanced Enzyme Technologies Ltd. is a Public Limited Listed company incorporated on 15/03/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Num…

This summary is generated from the stock page data available for Advanced Enzyme Technologies Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

61
Advanced Enzyme Technologies Ltd scores 61/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health72/100 · Strong
ROCE 13.1% GoodROE 9.5% AverageD/E 0.01 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 13.95% (6mo) AccumulatingDII holding down 2.68% MF sellingPromoter holding at 43.0% Stable
Earnings Quality50/100 · Moderate
OPM stable around 32% Steady
Quarterly Momentum58/100 · Moderate
Revenue (4Q): +13% YoY GrowingProfit (4Q): +13% YoY PositiveOPM: 29.0% (down 4.0% YoY) Margin pressure
Industry Rank60/100 · Moderate
P/E 23.2 vs industry 59.5 Cheaper than peersROCE 13.1% vs industry 16.4% Average3Y sales CAGR: 6% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 25, 2026, 10:12 pm

Market Cap 3,347 Cr.
Current Price 299
Intrinsic Value₹182.58
High / Low 367/252
Stock P/E23.2
Book Value 133
Dividend Yield1.74 %
ROCE13.1 %
ROE9.54 %
Face Value 2.00
PEG Ratio4.71

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Advanced Enzyme Technologies Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Advanced Enzyme Technologies Ltd 3,347 Cr. 299 367/25223.2 1331.74 %13.1 %9.54 % 2.00
Aarti Drugs Limited 3,347 Cr. 367 575/31918.0 1470.55 %13.5 %13.0 % 10.0
RPG Life Sciences Ltd 3,363 Cr. 2,033 2,725/1,73132.0 3350.98 %32.8 %25.5 % 8.00
Gufic BioSciences Ltd 2,991 Cr. 298 409/26859.2 62.70.03 %13.2 %12.3 % 1.00
SMS Pharmaceuticals Ltd 3,715 Cr. 397 448/20542.6 81.20.10 %12.2 %11.0 % 1.00
Industry Average19,737.15 Cr1,103.0859.48201.130.36%16.35%15.16%6.10

All Competitor Stocks of Advanced Enzyme Technologies Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 142139147158161158155146169167186185172
Expenses 10095103107107102103104114122129124123
Operating Profit 42444451545551425546566049
OPM % 29%32%30%32%33%35%33%29%33%27%30%33%29%
Other Income 977614-67108991020
Interest 1111111111111
Depreciation 98999999910101010
Profit before tax 40424148594049425343556058
Tax % 31%24%29%27%28%25%28%21%27%38%26%25%26%
Net Profit 28322935423035333927404543
EPS in Rs 2.632.872.583.083.742.533.052.943.372.373.573.873.80

Last Updated: February 6, 2026, 8:47 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 18, 2026, 2:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 239222293329391420444502529541624637710
Expenses 189131155177226236241269327382418441498
Operating Profit 5091138152165184203232203158206196211
OPM % 21%41%47%46%42%44%46%46%38%29%33%31%30%
Other Income 11-331569621213348
Interest 13984954333453
Depreciation 109913182126283535353740
Profit before tax 2874118137139162179210171140188187216
Tax % 23%31%35%32%33%28%26%28%28%26%27%28%
Net Profit 2151779394116133151124104137134155
EPS in Rs 1.854.606.978.208.079.9511.5813.0910.709.4511.9211.7213.61
Dividend Payout % 6%4%3%5%6%6%5%7%9%11%43%44%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)142.86%50.98%20.78%1.08%23.40%14.66%13.53%-17.88%-16.13%31.73%-2.19%
Change in YoY Net Profit Growth (%)0.00%-91.88%-30.20%-19.70%22.33%-8.75%-1.12%-31.41%1.75%47.86%-33.92%

Advanced Enzyme Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:11%
5 Years:7%
3 Years:6%
TTM:6%
Compounded Profit Growth
10 Years:10%
5 Years:0%
3 Years:3%
TTM:-8%
Stock Price CAGR
10 Years:%
5 Years:8%
3 Years:8%
1 Year:-25%
Return on Equity
10 Years:14%
5 Years:11%
3 Years:10%
Last Year:10%

Last Updated: September 4, 2025, 10:20 pm

Balance Sheet

Last Updated: April 3, 2026, 9:18 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 22222222222222222222222222
Reserves 1451882564425376578179481,0661,2131,3021,3981,462
Borrowings 16711510154673528233534473935
Other Liabilities 7392716510291104153137142150151173
Total Liabilities 4064174505837278059711,1461,2601,4111,5211,6111,692
Fixed Assets 287287285421491495563601619649650679683
CWIP 2578111010101522412231
Investments 00000111124121102360403480529
Other Assets 117125158153226188275413524380427430449
Total Assets 4064174505837278059711,1461,2601,4111,5211,6111,692

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 435493107116129141163122140141142
Cash from Investing Activity + -25-15-10-60-60-124-43-272-286-65-89
Cash from Financing Activity + -20-36-63-65-2-43-39-26-48-26-59-73
Net Cash Flow -1221-1854-386010975-17117-20
Free Cash Flow 34428897105116901439510294108
CFO/OP 126%88%88%105%97%70%69%94%87%112%93%103%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-117.00-24.0037.0098.0098.00149.00175.00209.00168.00124.00159.00157.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 496152555551616361685866
Inventory Days 387403358352339363361346402343375378
Days Payable 818968577846435660674041
Cash Conversion Cycle 356374342351315369379353404344393403
Working Capital Days -54-4337647729094116109102112
ROCE %12%25%36%31%25%24%22%22%15%12%15%13%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 49.88%46.52%45.92%43.62%43.50%43.02%42.95%42.92%43.08%43.08%43.08%43.04%
FIIs 21.86%21.89%22.27%22.54%23.01%12.03%12.63%12.57%11.90%23.45%25.41%25.85%
DIIs 5.73%7.58%6.49%6.98%7.56%8.08%8.02%8.17%8.19%8.45%6.41%5.51%
Public 22.54%24.02%25.34%26.88%25.95%36.87%36.40%36.31%36.82%25.00%25.09%25.62%
No. of Shareholders 77,53775,05272,64273,03468,64065,22266,75867,35165,32267,58969,63768,051

Shareholding Pattern Chart

No. of Shareholders

Advanced Enzyme Technologies Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
UTI MNC Fund 1,037,821 1.12 30.8N/AN/AN/A
ICICI Prudential ESG Exclusionary Strategy Fund 872,022 1.82 25.88N/AN/AN/A
Bank of India ELSS Tax Saver 38,876 0.08 1.15118,1512026-02-21 03:10:27-67.1%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 11.7211.929.4510.7013.09
Diluted EPS (Rs.) 11.7111.929.4510.6813.07
Cash EPS (Rs.) 15.2415.4012.4214.2016.10
Book Value[Excl.RevalReserv]/Share (Rs.) 127.00122.61114.84102.0092.25
Book Value[Incl.RevalReserv]/Share (Rs.) 127.00122.61114.84102.0092.25
Revenue From Operations / Share (Rs.) 56.9355.7948.3547.3544.92
PBDIT / Share (Rs.) 20.3321.5616.2718.5921.51
PBIT / Share (Rs.) 17.0618.4113.1315.4618.97
PBT / Share (Rs.) 16.7516.8012.5515.3018.83
Net Profit / Share (Rs.) 11.9712.259.2911.0713.56
NP After MI And SOA / Share (Rs.) 11.7211.929.4510.7013.08
PBDIT Margin (%) 35.7138.6433.6439.2647.89
PBIT Margin (%) 29.9733.0027.1632.6542.23
PBT Margin (%) 29.4130.1025.9632.3141.91
Net Profit Margin (%) 21.0321.9519.2123.3830.18
NP After MI And SOA Margin (%) 20.5821.3619.5322.5829.13
Return on Networth / Equity (%) 9.2210.068.5510.9815.06
Return on Capital Employeed (%) 12.5214.4010.9214.3119.53
Return On Assets (%) 8.088.687.429.4312.68
Long Term Debt / Equity (X) 0.010.010.010.010.01
Total Debt / Equity (X) 0.010.010.010.010.01
Asset Turnover Ratio (%) 0.400.420.330.320.38
Current Ratio (X) 9.097.619.3110.007.64
Quick Ratio (X) 7.476.227.718.006.25
Inventory Turnover Ratio (X) 4.171.141.231.301.32
Dividend Payout Ratio (NP) (%) 43.4941.9410.588.414.58
Dividend Payout Ratio (CP) (%) 34.0133.177.946.503.83
Earning Retention Ratio (%) 56.5158.0689.4291.5995.42
Cash Earning Retention Ratio (%) 65.9966.8392.0693.5096.17
Interest Coverage Ratio (X) 63.9582.3575.13115.72150.80
Interest Coverage Ratio (Post Tax) (X) 38.6652.9445.5869.9396.02
Enterprise Value (Cr.) 3081.993814.492529.422942.983729.91
EV / Net Operating Revenue (X) 4.846.114.685.567.43
EV / EBITDA (X) 13.5515.8213.9114.1615.52
MarketCap / Net Operating Revenue (X) 4.906.234.795.967.68
Retention Ratios (%) 56.5058.0589.4191.5895.41
Price / BV (X) 2.202.932.102.903.97
Price / Net Operating Revenue (X) 4.906.234.795.967.68
EarningsYield 0.040.030.040.030.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Advanced Enzyme Technologies Ltd. is a Public Limited Listed company incorporated on 15/03/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24200MH1989PLC051018 and registration number is 051018. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 351.41 Cr. and Equity Capital is Rs. 22.38 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsA - Wing, Sun Magnetica, 5th Floor, LIC Service Road, Thane Maharashtra 400604Contact not found
Management
NamePosition Held
Mr. Vasant RathiNon Executive Chairman
Mr. Mukund KabraWhole Time Director
Ms. Rasika RathiNon Executive Director
Dr. Sunny SharmaNon Executive Director
Mr. Pramod KasatIndependent Director
Mrs. Vandana TilakIndependent Director
Ms. Rajshree PatelIndependent Director
Mr. Nitin DesmukhIndependent Director
Mr. Vinodkumar JajooIndependent Director

FAQ

What is the intrinsic value of Advanced Enzyme Technologies Ltd and is it undervalued?

As of 29 April 2026, Advanced Enzyme Technologies Ltd's intrinsic value is ₹182.58, which is 38.94% lower than the current market price of ₹299.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (9.54 %), book value (₹133), dividend yield (1.74 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Advanced Enzyme Technologies Ltd?

Advanced Enzyme Technologies Ltd is trading at ₹299.00 as of 29 April 2026, with a FY2026-2027 high of ₹367 and low of ₹252. The stock is currently in the middle of its 52-week range. Market cap stands at ₹3,347 Cr..

How does Advanced Enzyme Technologies Ltd's P/E ratio compare to its industry?

Advanced Enzyme Technologies Ltd has a P/E ratio of 23.2, which is below the industry average of 59.48. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Advanced Enzyme Technologies Ltd financially healthy?

Key indicators for Advanced Enzyme Technologies Ltd: ROCE of 13.1 % is moderate. Dividend yield is 1.74 %.

Is Advanced Enzyme Technologies Ltd profitable and how is the profit trend?

Advanced Enzyme Technologies Ltd reported a net profit of ₹134 Cr in Mar 2025 on revenue of ₹637 Cr. Compared to ₹124 Cr in Mar 2022, the net profit shows an improving trend.

Does Advanced Enzyme Technologies Ltd pay dividends?

Advanced Enzyme Technologies Ltd has a dividend yield of 1.74 % at the current price of ₹299.00. The company pays dividends, though the yield is modest.

Last Updated: April 25, 2026, 10:12 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 540025 | NSE: ADVENZYMES
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Advanced Enzyme Technologies Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports